Organic compounds -- part of the class 532-570 series inventions 01/09

20090030206 - Method for producing quaterrylene-3,4:13, 14-tetracarboxy diimides by direct synthesis: P

20090030207 - Polymorphs of dolasetron base and process for preparation thereof: The present invention provides polymorphic forms of dolasetron base and methods for their use and preparation.... Agent: Kenyon & Kenyon LLP

20090030208 - (+) - and (-) -8-alkyl-3-(trifluoralkylsulfonyloxy)-8-azabicyclo(3.2.1.)oct-2-ene: e

20090030209 - Method for producing pentacyclic taxans: A compound of formula (1) (wherein R1 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or a heterocyclic group; R2 is a hydroxyl group optionally having a protective group) is processed with an alkali metal permanganate to produce a compound of formula... Agent: Sughrue-265550

20090023926 - Trityl derivatives for enhancing mass spectrometry: The present invention provides a compound of the formula: (IIa); having a reactive functional group M, capable of reacting with a biopolymer, BP, having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula: (IIIa). The biopolymer derivatives... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090023927 - Process for producing tricyclic ketone: In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresponds to a CDE ring moiety of a camptothecin (CPT) skeleton.... Agent: Wolf Greenfield & Sacks, P.c.

20090018338 - Treatment of crth2-mediated diseases and conditions: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090018339 - Process for preparing crystalline form a of lansoprazole: The present invention relates to a process for preparing Crystalline Form A of Lansoprazole. Specifically, the present invention relates to a process for preparing highly pure Crystalline Form A of Lansoprazole in a large scale without any additional conversion step, even by using ethanol in which Crystalline Form B is... Agent: Birch Stewart Kolasch & Birch

20090018340 - Formation of tetra-substituted enamides and stereoselective reduction thereof: The present invention is directed to a practical process for the preparation of an enamide (II) by palladium catalyzed coupling of a primary amide (IV) with a compound of structural formula (III), as shown below: As well as to crystalline forms of a compound produced by this process, in particular,... Agent: Merck And Co., Inc

20090012298 - Process for the preparation of rapamycin derivatives: Processes for the production of a 32-deoxorapamycin from a 32-iodo- or 32-hydroxyrapamycin, wherein the hydroxy group is substituted by the residue of an arylthionocarbonate or an arylthiocarbamate, in the presence of tris(trimethylsilyl)-silan and α,α′-azo-isobutyronitril in organic solvent; and 32-deoxorapamycin in the form of a crystalline solvate.... Agent: Novartis Corporate Intellectual Property

20090012299 - Pyrazolo-pyridinone compounds and methods of use thereof: wherein A1, A2, A3, A4, B, R1, R2, R3, R4 and R5 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary... Agent: Amgen Inc.

20090012300 - Process for the preparation of an (hetero) arylamine: The present invention relates to a process for the preparation of an (hetero)arylamine, wherein an optionally substituted (hetero)aromatic bromide compound is contacted with a nucleophilic organic nitrogen-containing compound in the presence of a base, and a catalyst comprising a copper atom or ion and at least one ligand, said ligand... Agent: Nixon & Vanderhye, PC

20090012301 - Fexofenadine crystal form and processes for its preparation thereof: Provided is a crystalline form of fexofenadine free base and processes for its preparation.... Agent: Kenyon & Kenyon LLP

20090012302 - Method of isolating a nucleic acid using a material containing an amino group and a carboxyl group and positively charged at a first ph and a solid material for nucleic acid isolation used for the method: Provided are a method of isolating a nucleic acid from a sample and a solid material for isolating the nucleic acid which can be used for the above method. The method includes contacting the sample with a bifunctional material containing an amino group and a carboxyl group at a first... Agent: Cantor Colburn, LLP

20090005563 - Conversion of thebaine to morphine derivatives: The present invention provides methods for the conversion of thebaine to a morphine derivative, such as hydrocodone. Novel ketal intermediates of the conversion are provided. A one-pot procedure for the conversion comprises treating thebaine with an acid in the presence of a metal catalyst.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090005564 - Methods for n-demethylation of morphine and tropane alkaloids: The present invention provides a method for the N-demethylation of an N-methylated heterocycle, particularly a morphine or tropane alkaloid or derivative thereof. The method comprises reacting the heterocycle with a metal catalyst and a solvent in the presence of an oxidizing agent.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090005565 - Methods for one-pot n-demethylation/n-acylation of morphine and tropane alkaloids: The present invention provides a method for the N-demethylation and/or N-acylation of an N-methylated heterocycle such as morphine alkaloids or tropane alkaloids. The method comprises reacting the heterocycle with an acylating agent in the presence of a metal catalyst.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090005566 - Method for making 1-substituted 1h-imidazo [4,5-c] quinolin-4-amine compounds and intermediates therefor: The present invention concerns a method for manufacturing 1-substituted 1H imidazo[4,5-c]quinolin-4-amine compounds through their corresponding formamides. The invention also concerns new formamide intermediates.... Agent: Birch Stewart Kolasch & Birch

20090005567 - Process for the preparation of 4-(8-chloro-5,6-dihydro-11h-benzo (5,6)-cyclohepta-(1,2b) -pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine): A process and new oxazolinic intermediates for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-clohepta-[1,2-b]-pyridin-11-ylide-ne)-1-piperidinecarboxylic acid ethyl ester (loratadine) is described. The process starts from 2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3-methyl-pyridine, a new intermediate to obtain loratadine. 2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-3-methyl-pyridine is condensed with 3-chloro-benzyl-chloride and the resultant product is treated with Grignard reagent of 4-chloro-N-methyl-piperidine. [3-(2-(3-chloro-phenyl)-ethyl]-pyridin-2-yl-]-1-(methyl-piperidin-4-yl)-methanone is obtained for subsequent hydrolysis.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090005568 - Substituted 2-aminothiazoles for treating neurodegenerative diseases: The invention relates to substituted 2-aminothiazole derivatives useful in treating disorders that are mediated by A2a receptor function, including neurodegenerative diseases including Parkinson's disease and inflammation. The compounds have general formula I:... Agent: Heslin Rothenberg Farley & Mesiti PC

20090005569 - Process for the preparation of 4-trifluoromethyl-2(1h)-pyridinone: 4-Trifluoromethyl-2(1H)-pyridinone is prepared from an alkyl vinyl ether and trifluoroacetyl chloride in a four step process.... Agent: Dow Agrosciences LLC

20090005570 - Method for preparing 2- (2-pyridinylmethylsulfinyl) benzimidazoles: The present invention provides a method for preparing an antiulcer agent, 2-(2-pyridinylmethylsulfinyl)benzimidazoles, such as Omeprazole, Lansoprazole, Pantoprazole and Rabeprazole, which includes oxidizing an intermediate having a linkage of methylthio group (—CH2S—) to methylsulfinyl (—CH2S(O)—) in the presence of an oxidation catalyst of an alkali metal salt of tungstate at a... Agent: Bacon & Thomas, PLLC

20090005571 - Process for preparing imino compounds: Process for preparing imine compounds, in which a carbonyl compound is reacted with a primary amine. The imine compound obtained in this way can be reacted further with a metalalkyl and subsequently a carbonyl compound to form an imine compound.... Agent: Lyondellbasell Industries